Firefly Neuroscience logo. Click to return to a homepage.

INVESTOR RELATIONS

Firefly Neuroscience, Inc.

CORPORATE OVERVIEW

Firefly is a medical technology and AI company developing and pioneering innovative neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The Company has developed its FDA-510(k) cleared Brain Network Analytics (“BNA”) software platform (the “BNA Platform”) and is focused on advancing diagnostic and treatment approaches for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder (ADHD). Over the last 15 years the Company has invested approximately $60 million to develop its BNA software, compile a database of brain wave tests, gain patent protection, and receive FDA approval to market and sell the Platform. As a result, Firefly is now pursuing commercial launch of the BNA Platform in multiple markets, including pharmaceutical companies with drug research and clinical trial activities and medical practitioners for use in their clinics.

news icon

LATEST RELEASES

A yellow arrow pointing to the right
chart icon

Stock Quote

NASDAQ: AIFF
0
Change
0 0
Volume
0
52 Weeks
0 - 0
Day
0 - 0
A yellow arrow pointing to the right

CONTACT IR

KCSA Strategic Communications

Valter Pinto or Jack Perkins

PH: (212) 896-1254

Firefly@KCSA.com

Share by: